{"id":"abemaciclib-fulvestrant","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"25-35","effect":"Leukopenia"},{"rate":"40-50","effect":"Diarrhea"},{"rate":"30-40","effect":"Fatigue"},{"rate":"25-35","effect":"Nausea"},{"rate":"20-30","effect":"Abdominal pain"},{"rate":"15-25","effect":"Vomiting"},{"rate":"20-30","effect":"Anemia"},{"rate":"10-20","effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL3301610","moleculeType":"Small molecule","molecularWeight":"506.61"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Abemaciclib is a selective CDK4/6 inhibitor that prevents phosphorylation of the retinoblastoma protein, halting G1/S cell cycle transition in hormone receptor-positive breast cancer cells. Fulvestrant is a selective estrogen receptor degrader (SERD) that binds to and promotes degradation of the estrogen receptor, eliminating ER-mediated signaling. The combination provides dual blockade of cell cycle and estrogen signaling pathways.","oneSentence":"Abemaciclib inhibits CDK4/6 to block cell cycle progression, while fulvestrant is an estrogen receptor antagonist that degrades the ER protein, together blocking hormone-driven breast cancer growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:21:36.732Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women"},{"name":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in premenopausal women (with endocrine therapy)"}]},"trialDetails":[{"nctId":"NCT05307705","phase":"PHASE1","title":"A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-05-11","conditions":"Breast Cancer","enrollment":193},{"nctId":"NCT07114601","phase":"PHASE1","title":"A Study of LY4257496 in Participants With Cancer (OMNIRAY)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-08-06","conditions":"Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm","enrollment":421},{"nctId":"NCT07174336","phase":"PHASE3","title":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-12-22","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":920},{"nctId":"NCT05573126","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","status":"RECRUITING","sponsor":"Ellipses Pharma","startDate":"2023-01-11","conditions":"Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer","enrollment":95},{"nctId":"NCT03643510","phase":"PHASE2","title":"Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-08-21","conditions":"Adenocarcinoma of Endometrium","enrollment":28},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT06380751","phase":"PHASE3","title":"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-01","conditions":"Advanced Breast Cancer","enrollment":500},{"nctId":"NCT04862663","phase":"PHASE3","title":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-05-10","conditions":"Locally Advanced (Inoperable) or Metastatic Breast Cancer","enrollment":895},{"nctId":"NCT05524584","phase":"PHASE2","title":"Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2022-08-31","conditions":"Breast Cancer, Metastatic Breast Cancer, Hormone Receptor-positive Breast Cancer","enrollment":20},{"nctId":"NCT06065748","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-12-11","conditions":"Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer","enrollment":1050},{"nctId":"NCT03531645","phase":"PHASE2","title":"Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-08-13","conditions":"Malignant Neoplasms of Female Genital Organs","enrollment":18},{"nctId":"NCT06486883","phase":"PHASE2","title":"Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype","status":"RECRUITING","sponsor":"MedSIR","startDate":"2025-06-30","conditions":"Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma","enrollment":200},{"nctId":"NCT06179303","phase":"PHASE2","title":"Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-07-22","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma","enrollment":60},{"nctId":"NCT06585969","phase":"PHASE3","title":"A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Danish Breast Cancer Cooperative Group","startDate":"2026-01-01","conditions":"Metastatic Breast Cancer, ER-positive Breast Cancer, Luminal B","enrollment":""},{"nctId":"NCT04923542","phase":"PHASE1, PHASE2","title":"Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-11-30","conditions":"Brain Metastases, HR+ Metastatic Breast Cancer","enrollment":31},{"nctId":"NCT02763566","phase":"PHASE3","title":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2016-12-05","conditions":"Breast Cancer","enrollment":463},{"nctId":"NCT05305924","phase":"PHASE2","title":"Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2021-02-25","conditions":"ER-Positive Breast Cancer, HER2-negative Breast Cancer","enrollment":28},{"nctId":"NCT02057133","phase":"PHASE1","title":"A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2014-03-10","conditions":"Breast Neoplasms","enrollment":198},{"nctId":"NCT05696626","phase":"PHASE3","title":"Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","status":"RECRUITING","sponsor":"Sermonix Pharmaceuticals Inc.","startDate":"2023-10-31","conditions":"Metastatic Breast Cancer","enrollment":500},{"nctId":"NCT05933395","phase":"PHASE2","title":"Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2024-09-23","conditions":"Advanced Breast Cancer","enrollment":135},{"nctId":"NCT05169567","phase":"PHASE3","title":"Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-03-11","conditions":"Breast Neoplasm, Neoplasm Metastasis","enrollment":368},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT06630325","phase":"PHASE2","title":"A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-24","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":30},{"nctId":"NCT07037199","phase":"PHASE2","title":"Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-18","conditions":"Advanced Breast Cancer","enrollment":45},{"nctId":"NCT04603183","phase":"PHASE2","title":"ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL","status":"COMPLETED","sponsor":"MedSIR","startDate":"2021-06-02","conditions":"Breast Cancer Metastatic","enrollment":162},{"nctId":"NCT06409390","phase":"PHASE2","title":"Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-08-14","conditions":"Metastatic Breast Cancer","enrollment":15},{"nctId":"NCT05867251","phase":"PHASE1, PHASE2","title":"Study of AVZO-021 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Avenzo Therapeutics, Inc.","startDate":"2023-08-30","conditions":"Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer","enrollment":430},{"nctId":"NCT07180160","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer","status":"RECRUITING","sponsor":"Wenjin Yin","startDate":"2025-09-25","conditions":"Advanced Breast Cancer","enrollment":123},{"nctId":"NCT03280563","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-12-22","conditions":"Breast Neoplasms","enrollment":144},{"nctId":"NCT05608252","phase":"PHASE1, PHASE2","title":"VS-6766+Abema+Fulv in Met HR+/HER- BC","status":"RECRUITING","sponsor":"Adrienne G. Waks","startDate":"2023-02-23","conditions":"Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer","enrollment":63},{"nctId":"NCT02107703","phase":"PHASE3","title":"A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2014-07-22","conditions":"Breast Neoplasms","enrollment":669},{"nctId":"NCT04681768","phase":"","title":"Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2020-12-22","conditions":"Breast Cancer/ Metastatic Breast Cancer","enrollment":95},{"nctId":"NCT03939897","phase":"PHASE1","title":"Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-17","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma","enrollment":24},{"nctId":"NCT04158362","phase":"PHASE3","title":"Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-06-11","conditions":"Cancer Metastatic","enrollment":180},{"nctId":"NCT05735080","phase":"PHASE1, PHASE2","title":"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer","status":"RECRUITING","sponsor":"Incyclix Bio","startDate":"2023-03-28","conditions":"Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor","enrollment":150},{"nctId":"NCT03425838","phase":"PHASE3","title":"Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Borstkanker Onderzoek Groep","startDate":"2017-11-09","conditions":"Breast Neoplasm Female","enrollment":1050},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT04227327","phase":"PHASE2","title":"Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)","status":"TERMINATED","sponsor":"University of Milano Bicocca","startDate":"2020-01-07","conditions":"Advanced Breast Cancer","enrollment":31},{"nctId":"NCT04352777","phase":"PHASE2","title":"Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer","status":"COMPLETED","sponsor":"Duke University","startDate":"2020-09-14","conditions":"Metastatic Breast Cancer, Locally Advanced Breast Cancer, Hormone Receptor Positive Tumor","enrollment":18},{"nctId":"NCT04975308","phase":"PHASE3","title":"A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2021-10-04","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":874},{"nctId":"NCT03099174","phase":"PHASE1","title":"This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-05-04","conditions":"Neoplasms, Breast Neoplasms","enrollment":133},{"nctId":"NCT05759949","phase":"PHASE1","title":"First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors","status":"COMPLETED","sponsor":"Relay Therapeutics, Inc.","startDate":"2023-03-29","conditions":"PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer","enrollment":41},{"nctId":"NCT05362760","phase":"PHASE4","title":"Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management","status":"RECRUITING","sponsor":"Prof. Wolfgang Janni","startDate":"2022-04-27","conditions":"Hormone Receptor-positive Metastatic Breast Cancer, HER2-negative Metastatic Breast Cancer","enrollment":300},{"nctId":"NCT04256941","phase":"PHASE2","title":"Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-31","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8","enrollment":4},{"nctId":"NCT02675231","phase":"PHASE2","title":"A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-05-23","conditions":"Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer","enrollment":237},{"nctId":"NCT06044623","phase":"PHASE3","title":"Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients","status":"RECRUITING","sponsor":"Region Örebro County","startDate":"2024-04-01","conditions":"Metastatic Breast Cancer, Advanced Breast Cancer, Quality of Life","enrollment":495},{"nctId":"NCT03227328","phase":"PHASE2","title":"CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2017-08-02","conditions":"Hormone Receptor Positive Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Negative Breast Cancer","enrollment":52},{"nctId":"NCT01394016","phase":"PHASE1","title":"A Phase 1 Study of LY2835219 In Participants With Advanced Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-12-07","conditions":"Advanced Cancer","enrollment":225},{"nctId":"NCT06561022","phase":"PHASE2","title":"Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-08-21","conditions":"Breast Cancer","enrollment":260},{"nctId":"NCT04092673","phase":"PHASE1, PHASE2","title":"Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies","status":"RECRUITING","sponsor":"Effector Therapeutics","startDate":"2019-10-25","conditions":"Solid Tumor, Adult","enrollment":30},{"nctId":"NCT06341283","phase":"","title":"A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2024-06-01","conditions":"Breast Cancer, Neoplasms, Breast Diseases","enrollment":200},{"nctId":"NCT05065411","phase":"PHASE3","title":"Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Veru Inc.","startDate":"2022-04-11","conditions":"Metastatic Breast Cancer","enrollment":5},{"nctId":"NCT04707196","phase":"PHASE4","title":"A Study of Abemaciclib in Indian Women With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-02-22","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":200},{"nctId":"NCT04920708","phase":"PHASE2","title":"Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression","status":"RECRUITING","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2022-12-28","conditions":"Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer","enrollment":324},{"nctId":"NCT04305236","phase":"PHASE2","title":"Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer","status":"TERMINATED","sponsor":"University of California, Irvine","startDate":"2020-07-23","conditions":"Breast Neoplasm, Hormone Receptor Positive Breast Carcinoma","enrollment":1},{"nctId":"NCT05789771","phase":"","title":"Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.","status":"COMPLETED","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2022-04-01","conditions":"HR+/HER2- Breast Cancer, Metastatic Disease, Аdvanced Disease","enrollment":136},{"nctId":"NCT04316169","phase":"PHASE1","title":"Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer","status":"WITHDRAWN","sponsor":"Medical College of Wisconsin","startDate":"2021-10-21","conditions":"Solid Tumor, Advanced Breast Cancer","enrollment":""},{"nctId":"NCT01655225","phase":"PHASE1","title":"A Study of LY3023414 in Participants With Advanced Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07-31","conditions":"Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma","enrollment":156},{"nctId":"NCT04031885","phase":"PHASE4","title":"A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2019-08-14","conditions":"Metastatic Breast Cancer","enrollment":4},{"nctId":"NCT04852081","phase":"","title":"Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2021-01-01","conditions":"Breast Cancer Stage IV","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Verzenios"],"phase":"marketed","status":"active","brandName":"Abemaciclib + Fulvestrant","genericName":"Abemaciclib + Fulvestrant","companyName":"Prof. Wolfgang Janni","companyId":"prof-wolfgang-janni","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abemaciclib inhibits CDK4/6 to block cell cycle progression, while fulvestrant is an estrogen receptor antagonist that degrades the ER protein, together blocking hormone-driven breast cancer growth. Used for Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women, Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in premenopausal women (with endocrine therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}